Overview
Corporate Video
Executive Management
Board of Directors
Board Committees
Corporate Governance
Scientific Advisory Board
Platform
Platform Overview
Publications
Pipeline
Pipeline Overview
SAB-195: CDI
SAB-176: Influenza
SAB-185: COVID-19
Partnering
Patients
C. diff Patient Information
Influenza
COVID-19
Expanded Access Policy
Media
News & Press Releases
Events
Presentations
Publications
Shareholder Services
Overview
SEC Filings
Stock Quote & Chart
Board of Directors
Corporate Governance
Board Committees
Analyst Coverage
RSS Feeds
Contact Us
Overview
Corporate Video
Executive Management
Board of Directors
Board Committees
Corporate Governance
Scientific Advisory Board
Platform
Platform Overview
Publications
Pipeline
Pipeline Overview
SAB-195: CDI
SAB-176: Influenza
SAB-185: COVID-19
Partnering
Patients
C. diff Patient Information
Influenza
COVID-19
Expanded Access Policy
Media
News & Press Releases
Events
Presentations
Publications
Shareholder Services
Overview
SEC Filings
Stock Quote & Chart
Board of Directors
Corporate Governance
Board Committees
Analyst Coverage
RSS Feeds
Contact Us
Home
>
News
>
Introduction to SAB’s Unique DiversitAb™ Immunotherapy Platform
October 13, 2021
Introduction to SAB’s Unique DiversitAb™ Immunotherapy Platform
Share
SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021
October 6, 2021
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
October 4, 2021
SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer
September 28, 2021
